IRIS
PATRIGNANI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.233
NA - Nord America 8.086
AS - Asia 3.538
Continente sconosciuto - Info sul continente non disponibili 22
AF - Africa 13
SA - Sud America 9
OC - Oceania 7
Totale 19.908
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.063
CN - Cina 1.842
UA - Ucraina 1.812
IE - Irlanda 1.431
TR - Turchia 1.210
GB - Regno Unito 1.192
SE - Svezia 881
IT - Italia 797
FR - Francia 761
DE - Germania 499
FI - Finlandia 340
RU - Federazione Russa 300
SG - Singapore 241
IN - India 184
PL - Polonia 95
CZ - Repubblica Ceca 47
BE - Belgio 45
EU - Europa 21
CA - Canada 17
VN - Vietnam 17
IL - Israele 13
IR - Iran 13
NL - Olanda 10
BR - Brasile 7
JP - Giappone 7
EG - Egitto 6
GR - Grecia 6
AU - Australia 5
MX - Messico 5
RO - Romania 5
ZA - Sudafrica 5
BY - Bielorussia 4
AE - Emirati Arabi Uniti 3
KR - Corea 3
AT - Austria 2
NZ - Nuova Zelanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
CG - Congo 1
CH - Svizzera 1
CL - Cile 1
CO - Colombia 1
EE - Estonia 1
ES - Italia 1
GT - Guatemala 1
HR - Croazia 1
ID - Indonesia 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
SC - Seychelles 1
SI - Slovenia 1
Totale 19.908
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.964
Chandler 1.728
Dublin 1.422
Southend 1.002
Princeton 705
Izmir 638
Dearborn 568
Nanjing 494
Cambridge 323
Wilmington 311
Beijing 284
Nanchang 199
Altamura 171
Ashburn 159
Boardman 157
Singapore 142
Chieti 135
Shenyang 132
Woodbridge 119
Ann Arbor 114
Hebei 93
Kraków 93
Grevenbroich 83
Tianjin 78
Jiaxing 74
Kunming 72
Changsha 67
Hangzhou 51
Norwalk 51
Jinan 44
Brussels 41
Orange 39
Brno 36
Los Angeles 35
Washington 35
Kocaeli 31
Hefei 28
Ningbo 28
Zhengzhou 26
Lanzhou 25
San Mateo 24
Augusta 23
Guangzhou 23
Houston 22
Auburn Hills 21
Helsinki 21
New York 21
Rome 20
Shanghai 19
Leawood 18
Dong Ket 17
Pescara 17
Seattle 17
Taizhou 17
Moscow 15
Spoltore 15
Düsseldorf 14
Changchun 13
Milan 13
Munich 13
Fuzhou 12
Tavagnacco 12
Toronto 11
Frontone 10
Hanover 10
Olomouc 10
Montesilvano 9
Ferrara 8
Tappahannock 8
Viterbo 8
Ardabil 7
Lanciano 7
Menlo Park 7
Torino 7
Falls Church 6
L’Aquila 6
Mugnano Di Napoli 6
Simi Valley 6
Verona 6
Walnut 6
Cape Town 5
Gavirate 5
Mexico City 5
Perm 5
San Vito Chietino 5
Avellino 4
Bari 4
Bologna 4
Cairo 4
Campobasso 4
Haikou 4
Mogilev 4
Mumbai 4
Naples 4
Padova 4
São Paulo 4
Andover 3
Baotou 3
Cedar Knolls 3
Chongqing 3
Totale 12.403
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 179
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 114
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 106
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 100
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 97
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 96
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. 95
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 94
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 93
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 91
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 90
LA CASCATA DELL'ACIDO ARACHIDONICO 89
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 88
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 88
Oxidative stress and platelet activation in essential hyperytension 87
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 87
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 87
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 86
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 85
Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. 85
Rare SNP rs12731181 in the miR-590-3p Target Site of the Prostaglandin F2α Receptor Gene Confers Risk for Essential Hypertension in the Han Chinese Population. 85
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 84
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 83
Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF-β1 82
Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting 82
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 82
New insights into COX-2 biology and inhibition. 81
Antithrombotic Agents and Cancer 81
Thromboxane biosynthesis and pulmonary function in cystic fibrosis 80
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 80
Therapeutic targeting of dysregulated cellular communication. 80
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 79
Pharmacodynamic of cyclooxygenase inhibitors in humans. 79
Platelet activation in patients with colorectal cancer. 79
Effetto del propranololo e del suo metabolita attivo 4-OH propranololo sui prostanoidi COX-2 derivati e sull’emossigenasi-1 (OH-1) in cellule HUVEC. 79
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 79
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 78
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 78
Induction of prostacyclin by steady laminar shear stress suppresses Tumor Necrosis Factor-alfa biosyntesis via Heme Oxygenase-1 in human endothelial cells. 77
Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. 76
Aspirin and Cancer 76
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 76
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 75
NCX 4040, a Nitric Oxide-Donating Aspirin, Exerts Anti-Inflammatory Effects through Inhibition of I{kappa}B-{alpha} Degradation in Human Monocytes. 75
Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. 75
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. 74
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 73
Usefulness of enzimatic intermediate markers-example of cox-2 inhibition 73
INCREASED THROMBOXANE PRODUCTION BY MONOCYTE PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. 73
INDUCTION OF PROSTACYCLIN BY STEADY LAMINAR SHEAR STRESS SUPPRESSES TUMOR NECROSIS FACTOR-ALPHA BIOSYNTHESIS VIA HEME OXYGENASE-1 IN HUMAN ENDOTHELIAL CELLS. 73
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 73
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 73
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 73
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 73
Mechanistic and pharmacological issues of aspirin as an anticancer agent 73
Aspirin, platelet inhibition and cancer prevention. 73
Repeated exposure to codeine alters morphine glucuronidation by affecting UGT gene expression in the rat. 73
A comparison of low-dose aspirin and dazoxiben as selective inhibitors of thromboxane A2 production in man. 72
RECOVERY OF THROMBOXANE BIOSYNTHESIS BY ASPIRIN-TREATED PLATELETS IN VITRO: A NOVEL MECHANISM OF ASPIRIN RESISTANCE. 72
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 72
HIPK2 regulates beta-catenin level and transcriptional potential 72
A SELECTIVE THROMBOXANE-SYNTHASE INHIBITOR, ON PLATELET AND RENAL PROSTAGLANDIN ENDOPEROXIDE METABOLISM. 71
IN VIVO FORMATION OF 8-ISO-PROSTAGLANDIN F2α AND ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN UNSTABLE ANGINA. 71
ALTERED RENAL AND PLATELET ARACHIDONIC ACID METABOLISM IN CIRRHOSIS. 71
Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. 71
Novel insights into the vasoprotective role of heme oxygenase-1. 71
P2Y12 Receptors in Tumorigenesis and Metastasis 71
Increased thromboxane production by monocyte prostaglandin endoperoxide synthase-2 in patients with acute myocardial infarction (pubbl. su Suppl. Circulation) 70
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 70
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 70
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 70
T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. 70
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 70
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 69
Low dose aspirin: how low, how often? 69
THE ROLE OF ARACHIDONIC ACID METABOLITE PGE2 ON T CELL PROLIFERATIVE RESPONSE. 69
Clinical pharmacology of selective COX-2 inhibitors. 69
Mechanistic aspects of COX-2 expression in colorectal neoplasia. 69
Induction of prostaglandin endoperoxide synthase 2 in monocytes of human whole blood is associated with cyclooxigenase-dependent isoprostane formation 68
CYLOOXYGENASE-INDEPENDENT INDUCTION OF THE TUMOR SUPPRESSOR PROTEIN P21WAF-1/CIP1 AND DIFFERENTIATION BY L-745,337, A SELECTIVE COX-2 INHIBITOR, AND SODIUM SALICYLATE, IN HT-29 COLON CANCER CELLS. 68
LOW-DOSE ASPIRIN IS A SELECTIVE INHIBITOR OF THROMBOXANE-RELATED PLATELET FUNCTION IN PATIENTS WITH MYOCARDIAL INFARCTION. 68
A double-blind randomized study of the anti-platelet effects of low-dose ASA and placebo in patients after myocardial infarction 68
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 68
BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF CYCLOOXYGENASE ACTIVITY OF HUMAN BLOOD PROSTAGLANDIN ENDOPEROXIDE SYNTHASES. 68
Fractional conversion of thromboxane (TX) B2 to urinary 2,3-dinor-TXB2 in the dog. 68
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 68
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. 68
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 68
A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. 68
DIFFERENTIAL CONTRIBUTION OF CYCLOOXYGENASE-ISOZYMES TO THE GENERATION OF PROSTACYCLIN AND PROSTAGLANDIN E2 BY ENDOTHELIAL CELLS IN RESPONSE TO STEADY LAMINAR SHEAR STRESSS. 67
Platelet-activating factor (PAF) receptor antagonists inhibit mitogen-induced human peripheral blood T-cell proliferation 67
Platelets, cyclooxygenases, and colon cancer. 67
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 67
Human pharmacology of naproxen sodium. 67
FARMACI ANTIINFIAMMATORI NON STEROIDEI 66
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 66
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 66
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 66
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 66
In vitro morphine metabolism by rat microglia. 66
Totale 7.753
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.892
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.892
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.964 0 324 22 233 255 361 581 484 120 162 406 16
2020/20212.195 343 3 340 13 236 427 48 42 170 349 85 139
2021/20221.264 12 16 38 202 122 9 25 103 123 25 192 397
2022/20234.632 374 433 179 589 495 970 291 409 626 55 90 121
2023/20241.827 163 100 131 53 100 456 496 36 7 35 17 233
2024/2025380 368 12 0 0 0 0 0 0 0 0 0 0
Totale 20.747